Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

Abstract

Outpatient-based iodine-125 prostate brachytherapy for prostate carcinoma classified as T1 or T2 resulted in biochemical outcomes comparable to end points resulting from radical prostatectomy and external beam radiation.